Merck KGaA's Margin Pressure Raises Execution Concerns

Merck KGaA's recent three-month share run of about 27% came to an end on August 7, when the stock closed at €143.65. However, this optimism was met with margin pressure in the company's earnings report. The trailing net profit margin slipped from 13.2% to 12.1%, even as the stock trades at a P/E of 24.7x and offers only a 1.53% dividend yield.

The company reported revenue of €5,133.7m and net income of €659.4m in Q2 2026, roughly flat against last year. This slight increase was not enough to offset the decline in profitability. Bears argue that Merck KGaA is stretching for growth while margins and execution risk move in the wrong direction.

Bulls, on the other hand, believe that the company can drive durable margin expansion by leaning into recurring life science revenue and a stronger healthcare pipeline. The recent quarter delivered several proof points for this growth engine, including the new BioReliance testing facility in Darmstadt and the FDA Breakthrough Therapy designation for enpatoran.

However, execution appears to be a key concern, as the translation of these newer growth platforms into higher and more resilient margins is not yet visible in the numbers. With Merck KGaA trading on a 24.7x P/E while margins drift and five-year earnings have declined, it remains to be seen whether liquidity, leverage, and cash coverage support this valuation.